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patients (mean age 65 years, mean Deyo-Charlson Comorbidity Index 0.6, mean
hospital length of stay 6.35 days); 214 cases and 214 controls were randomly se-
lected from the cohort for chart data analysis. In the 12 months post-index arthro-
plasty, there were 830 (2.5%) patients who had SSI, 644 (1.9%) who had SSB, and 84
(0.3%) who developed VTE. Of all SSI events, 65% occurred by 90 days following
arthroplasty. Significantly more patients who had received post-discharge throm-
boprophylaxis versus those that did not developed SSI but not SSB (SSI: 28.4% vs
23.2% [P0.0001]; SSB:28.5% vs 23.3% [P0.07]). In the logistic regression analysis,
only the duration of surgery (P0.004), surgical revision (P0.04), and rehospital-
ization (P0.001) emerged as independent predictors of SSI. CONCLUSIONS: Post-
discharge thromboprophylaxis and SSB were not associated with post-operative
SSI, thus dispelling concerns about the increased risk of developing SSI due to
prolonged SSB associated with the use of pharmacologic thromboprophylaxis. Ad-
ditional studies are needed to endorse these findings in similar patient popula-
tions.
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OBJECTIVES: The risk of post-discharge venous thromboembolism (VTE) and
bleeding in total knee and hip arthroplasty (TKA/THA) has not been completely
elucidated because interventions to reduce these adverse outcomes have evolved
rapidly. The objective of this study was to determine the incidence of these events
and associated risk factors, and to evaluate the use of thromboprophylaxis.
METHODS: Administrative medical records (2004–2009) from a large healthcare
plan were linked to an inpatient database of 450 hospitals in the United States.
Adult patients undergoing TKA or THA with no evidence of prior orthopaedic sur-
geries, prior VTE, post-discharge revision surgeries, or death were included. ICD-
9-CM diagnosis and CPT/HCPC procedure codes were used for evaluating symp-
tomatic VTE and bleeding rates 90 days post-surgery. Multivariate analyses were
performed to identify predictors of VTE and bleeding after hospitalization.
RESULTS: Two hundred twenty-six of 9167 patients (2.5%; 3109 THA, 6058 TKA)
with amedian age of 60 years and amean Charlson-Quan comorbidity index score
of 0.5 experienced VTE, and 324 (3.5%) had bleeding. Most of these events occurred
post-discharge (70% and 79%, respectively). Over 50% of VTE occurred within 30
days post-discharge. Consistent predictors of VTE and bleeding after hospitaliza-
tion were inpatient VTE or bleeding, respectively, and all-cause rehospitalization.
Post-discharge thromboprophylaxis was not a significant risk factor for bleeding.
Ninety-eight percent of patients received thromboprophylaxis during hospitaliza-
tion; 26% received it post-discharge. During hospitalization, three-fourths of pa-
tients received enoxaparin and/or warfarin, often in combination withmechanical
prophylaxis devices (57%). Post-discharge, mean antithrombotic drug exposure
was 7.4 days. CONCLUSIONS: Patients who experience VTE or bleeding during
hospitalization and patients who are rehospitalized are at greatest risk of throm-
boembolic and bleeding outcomes, respectively, post-discharge. These data also
suggest that the use of thromboprophylaxis following hospitalization should not
significantly increase the risk of post-discharge bleeding after TKA/THA.
PCV5
INTRA-ARTERIAL THROMBOLYSIS VERSUS STANDARD TREATMENT OR
INTRAVENOUS THROMBOLYSIS IN ADULTS WITH ACUTE ISCHEMIC STROKE: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Nam J, He J, O’Reilly D
PATH Research Institute, McMaster University, Hamilton, ON, Canada
OBJECTIVES: Recent evidence has suggested that intra-arterial thrombolysis (IAT)
may provide benefit beyond intravenous thrombolysis (IVT) in ischemic stroke
patients. Previous meta-analyses have only compared IAT to standard treatment
[without thrombolysis]. The objective was to review the benefits and harms of IAT
in ischemic stroke patients. METHODS: EMBASE, MEDLINE, the Cochrane registry
and the stroke trials registry were queried from inception to 2011. Two reviewers
independently screened titles and abstracts for randomized controlled trials of
ischemic stroke comparing IAT to either IVT or standard treatment. Primary out-
comes included good functional outcome, excellent functional outcome, mortality
and symptomatic intracranial hemorrhage. Results were stratified by comparison
treatment. RESULTS: A total of 543 citations were identified. Two trials (n81)
compared IAT to IVT while the remaining four trials (n351) compared IAT to
standard treatment. IAT increased good functional outcome by 47% when com-
pared to standard treatment (RR1.47; 95%CI1.07-2.22; I20) and 74%when com-
pared to IVT (RR1.74; 95%CI1.01-3.01; I20). Excellent functional outcome was
73% higher with IATwhen compared to standard treatment (RR1.73; 95%CI1.17-
2.57; I20) and not significantly different when compared to IVT (RR1.74;
95%CI0.85-3.56), though only one trial reported results for the latter. IAT did not
increase mortality when compared to standard treatment (RR0.82; 95%CI0.56–
1.21; I20) or IVT (RR1.12; 95%CI0.47–2.68; I20). Syptomatic intracranial hem-
orrhage, however, was almost 4 times higher with IATwhen compared to standard
treatment (RR3.90; 95%CI1.41–10.76; I20)while not significantly differentwhen
compared to IVT (RR1.13; 95%CI0.32–3.99; I242%). CONCLUSIONS: Compared
to standard treatment, IAT increases good and excellent functional outcomes;
compared to IVT, IAT increases good functional outcome. As well, IAT does not
increase mortality over IVT or standard treatment. However, IAT increases symp-
tomatic intracranial hemorrhage compared to standard treatment while the risk
remains comparable to IVT. Imprecise pooled estimates for good and excellent
functional outcome prevent any overtly strong recommendation for the use of IAT.
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OBJECTIVES: Evidence regarding the effect of concomitant use of clopidogrel and
proton pump inhibitors (PPIs) on adverse cardiovascular outcomes remains incon-
clusive. The purpose of the current studywas to examine the effect of concomitant
use of clopidogrel and PPI in a national sample of elderly Medicare beneficiaries
(age 65 years).METHODS: The study used a nested case-control design. A cohort
of Medicare beneficiaries taking clopidogrel for any period between July 1, 2006 and
December 31, 2008 was identified from a 5% national sample of Medicare claims
data using prescription records. Beneficiaries who had a gap of more than 30 days
between clopidogrel fills were excluded. Within the continuous clopidogrel user
cohort, cases [beneficiaries who experienced amajor adverse cardiovascular event
(MACE, composite of acute myocardial infarction, coronary artery bypass graft,
percutaneous coronary intervention, stroke, and mortality)] and controls (benefi-
ciaries who did not experience a MACE) were identified from inpatient and outpa-
tient claims. Concomitant use of clopidogrel and PPI was ascertained using pre-
scription drug records. Each case wasmatched to a control on age and time to start
clopilogrel using a greedy match algorithm. Conditional logistic regression was
conducted on the matched sample to evaluate the association between concomi-
tant use and occurrence of a MACE. RESULTS: A cohort of 43,159 clopidogrel users
was identified. 15,722 of them (36.4%) used clopidogrel and PPI concomitantly at
any time during the study period. 9,332 cases were identified andmatched to equal
number of controls. Beneficiaries using clopidogrel and PPI concomitantly were
more likely to experience a MACE as compared to beneficiaries receiving clopi-
dogrel only (odds ratio: 1.411, 95% Confidence Interval: 1.322 – 1.506).
CONCLUSIONS: Concomitant use of clopidogrel and PPI was associated with an
increased risk of experiencing a cardiovascular adverse event. Caution should be
exercised when co-prescribing the two medications to elderly patients.
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OBJECTIVES: To quantify the impact of atrial fibrillation (AF) and major AF comor-
bidities on risk of cardiovascular (CV) hospitalization (CVH). METHODS: This ret-
rospective cohort study assessed an administrative claims database (Thomson
Reuters’ MarketScan) for newly diagnosed AF patients and demographically
matched non-AF patients to characterize risk of comorbidities and CVH among AF
patients. Patients aged40 yearswith364 days in the databasewere identified by
a qualifying AF diagnosis (2 outpatient diagnoses within 30 days of each other or
1 inpatient diagnosis) from January 1, 2004 to June 29, 2009. RESULTS: A total of
210,524 patients were included (mean age 74.012.5 years, 49% male, 68% Medi-
care). Compared with non-AF patients, AF patients were more likely prescribed
beta blockers (44% vs. 22%), digoxin (15% vs. 2%), and anticoagulants (29% vs. 2%);
had a higher severity of illness (Charlson Comorbidity Index score 4; 16.5% vs.
4.1%); and had higher comorbidity prevalence (odds ratio; 95% confidence interval):
myocardial infarction (13.1; 11.7-14.7), heart failure (HF; 9.2; 8.9-9.6), and pulmo-
nary embolism (8.2; 7.2-9.5). Risk of new CV events and comorbidities at follow-up
was significantly (P0.0001) higher inAFpatients,most notablymajor bleeding, HF,
valvular disease, and stroke. AF patients with baseline comorbidities related to
CHADS2 (score2) or CHA2DS2-VASc (score4) experienced2.5-fold higher rates
of overall CVH. AF patients had 3.4-fold higher CVH risk with30% hospitalized at
1 year vs. 8% of non-AF patients; 24.3% of AF patients experienced recurrent AF
requiring hospitalization (incidence: 176/1000 person-years). CONCLUSIONS: AF
patients have higher burden of baseline CV comorbidities that portend greater risk
of CVH and new CV comorbidities following diagnosis compared to matched
non-AF patients. These data indicate AF recurrence requiring hospitalization and
overall hospitalizations 1 year following diagnosis is common.
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OBJECTIVES: Time in therapeutic range (TTR) may be a quality indicator for anti-
coagulation. Previous studies have demonstrated that heart failure (HF) and other
comorbidities are associated with poorer anticoagulation control; however, this
associationwas not studied in a representative US population. The objectivewas to
determine the association between HF, other comorbidities, patient characteris-
tics, and TTR among patients with nonvalvular atrial fibrillation (NVAF).
METHODS: We analyzed longitudinal patient-level anticoagulation management
records collected between 2006 and 2010 by decision support software, Coag-
Clinic™. Adult patients with NVAF who used warfarin over 12 months with no gap
60 days between visits were identified. The Rosendaal method was used to cal-
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culate TTR, and TTR 55% was defined as “lower TTR”. CHADS22 was defined as
“higher CHADS2”. Logistic regression analyses were conducted to determine the
association between comorbidities and TTR. RESULTS: We identified 23,425 pa-
tients. The mean (SD) age was 74.89.7 years, with 84.8% 65 years. The most
common comorbidities were hypertension (41.7%), diabetes (24.1%), HF (11.7%),
and stroke (11.1%). The mean (SD) TTR was 67.314.4; 18.7% of patients had
“lower TTR”. In multivariable analyses, using age, gender, hypertension, diabetes,
stroke, and region as covariates, HF was associated with “lower TTR” [adjusted OR
(95%CI)  1.41 (1.28, 1.56); p.001]. Diabetes [1.28 (1.19, 1.38); p.001], and stroke
[1.15 (1.04, 1.27); p.001] were also associated with “lower TTR”. In the second
multivariable analyses, using gender, and region as covariates, “higher CHADS2”
was associated with “lower TTR” [adjusted OR (95%CI)  1.11 (1.04, 1.18); p.001].
CONCLUSIONS:Common comorbidities that accompanyNVAF are associatedwith
“lower TTR”. HF was associated with the greatest likelihood of a “lower TTR”, fol-
lowed by diabetes, then stroke. Anticoagulation control is more challenging for
patients with these conditions. Novel agents offering a predictable dose-response
may benefit these patients.
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OBJECTIVES: Patients with Afib have higher risk of stroke than those without Afib.
Anticoagulant therapy prevents strokes in Afib, however, Afib patients with mod-
erate to severe renal impairment have been excluded from trials. The objective of
this study was to assess the distribution of renal function by estimated glomerular
filtration rate (eGFR) in Afib patients. METHODS: A retrospective, cohort design
study was conducted using an EMR database. The study period was January 1996
thru December 2010 [eligibility period: 1/2006 - 12/2009 for adults diagnosed with
Afib (ICD9 code 427.31)]. IndexDatewas first Afib diagnosis during eligibility period.
The pre-index periodwas Jan 1996 to Index and the post-index period defined as 12
months post Index. Serum creatinine measurement at Index was required. Renal
function categorized by NKF Guidelines for Stage of CKD and eGFR calculated using
Cockcroft-Gault Equation. Demographic and clinical characteristicswere collected,
baseline and follow-up renal function determined and logistic regression con-
ducted to assess predictors of renal function decline. RESULTS: A total of 61,840
Afib patients (mean age 69.8 years; 54.2% male) identified and categorized by CKD
stage (mean age; % male) at Index: Normal – 6,572 (58.5; 73.0%); Stage 1 – 10,901
(62.8; 68.6%); Stage 2 – 20,331 (71.3; 58.6%); Stage 3 – 21,105 (74.9; 39.5%); Stage 4 –
2,579 (75.1; 31.1%); Stage 5 – 352 (71.8; 48.9%). Post-index patients were categorized
by CKD stage: Normal – 11,788; Stage 1 – 2799; Stage 2 – 17,009; Stage 3 – 18,849;
Stage 4 – 2675; Stage 5 – 401 (8,319 patients with no post-index eGFR). Male gender
and increasing age and Charlson Comorbidity Index were predictors of renal func-
tion decline (10%) as well as CHD, CKD, DM, HF, HTN and proteinuria (p0.05).
CONCLUSIONS: Nearly 40% of Afib patients in this study exhibited moderate to
severe renal impairment.
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OBJECTIVES: To assess the impact of real life statin utilization on the risk of first
non-fatal myocardial infarction (MI). METHODS: Design: Case-control methodol-
ogy using the pharmacoepidemiological information system “PGRx”. Data on co-
morbidities, risk factors andmedications were obtained frommedical records and
patient telephone interviews. Setting: General practices (n371) and cardiology
centres (n60) across France. Participants: Cases were patients with the first MI 
1 month before the date of recruitment (n2238). Controls were patients seen by a
general practitioner (GP) with no restriction as to the reasons of consultation
(n2238), matched to MI cases on gender, age, frequency of visits to a doctor, date
of recruitment and personal history of non-cardiovascular chronic disease. Expo-
sure: Statin exposure was defined as any utilisation in the two-year prior to date of
MI in cases or recruitment date in controls.Main outcomemeasures: Adjusted odds
ratios (OR) of the risk of first MI was estimated by multiple conditional logistic
regression models. Comparative effectiveness and propensity to use of individual
statinmolecules were assessed. RESULTS: The use of statins was associatedwith a
lower MI risk, with adjusted OR 0.67 [95% CI 0.56 - 0.79] for current use (within 2
months before the index date) and 0.73 [0.62 –0.86] for any use within 24 months.
Among individual statins, rosuvastatin was associated with the lowest MI risk
(adjusted OR 0.49 [0.35 - 0.68] for any use in 24 months preceding the index date)
followed by simvastatin (0.62 [0.46 - 0.84]) and others. CONCLUSIONS: This is the
first major population-based field study to investigate the effect of statins on the
risk of first non-fatal MI in a real life situation. We observed similar risk reduction
as in recent meta-analyses. While most individual statin molecules displayed pro-
tective effect, their effectiveness varied depending onpatient profile and treatment
patterns.
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OBJECTIVES:Although studies have investigated the epidemiology of patientswith
atrial fibrillation (AF), research in Japan is lacking. The aim of the current studywas
to assess the patient characteristics, medication use, and comorbidities of an AF
sample from a representative data source in Japan to make broad cross-region
comparisons.METHODS:The 2008, 2009, and 2010 JapanNational Health andWell-
ness Survey (NHWS) datasets were used in this study. The NHWS is an Internet-
based survey administered to the adult population in Japan using a random strat-
ified sampling framework to ensure demographic representativeness. Only
patients who reported a diagnosis of AF (N565) in these datasets were included in
the analyses. Demographics, health characteristics, stroke risk (using the
CHA2DS2-VASc score), and comorbidities were all assessed. RESULTS: Most pa-
tients were male (83.5%), 60 years or older (77.0%), weighed 64.50 kilograms
(SD11.04), and had been diagnosed for 10.4 years (standard deviation10.6).
Nearly a fifth (19.1%) continued to smoke. Based on the CHA2DS2-VASc score, 11.5%
patients were of low stroke risk, while 35.4% and 53.1% were of moderate and high
risk, respectively. Despite this risk for stroke, only 64.2% of patients were currently
being treated for AF. Patients with AF also reported a number of comorbidities
including 87.1% with another cardiovascular condition, 67.8% with a urological
condition, 37.3% with dyspepsia, and 32.7% with pain. A total of 8.0% of patients
reported a previous myocardial infarction. CONCLUSIONS: The AF population in
Japan is somewhat unique in its dramatic gender split and lower body weight.
Additionally, most AF patients in Japan, through a combination of their behaviors
(e.g., smoking) and health characteristics, are at moderate-to-high risk for a future
stroke. Despite this risk, not all patients are being treated according to current
guidelines. Further, these patients suffer from a number of comorbidities which
can complicate treatment decisions.
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OBJECTIVES:Heart failure (HF) accounts for an excess hospitalization burden in the
United States, and consumption of health care costs. An aging population, eco-
nomic pressures with loss of regular insurance, and increasing co-morbidity
beckon a contemporary analysis of outcomeswithin a nestedMedicaid population.
METHODS: Medical/prescription/enrollment records from the Maryland State
Medicaid Managed Care Organization/Fee-for-service populations were used to
follow 18-64 year olds with a diagnosis of HF between 7-1-05 and 6-30-10 for  6
months. Cox-proportional hazard models assessed the impact of COPD, CVD,
stroke, and renal dysfunction on hospitalization risk post-HF, adjusting for demo-
graphics, disease modifying therapies for HF (ACE inhibitors, ARB, -Blockers, al-
dosterone antagonists, other CV drugs), andwhether diagnosis coincidedwith first
hospitalization. RESULTS: Of 13,192 HF patients, 71% were 45-64 years old, 44%
men, 60% African-American, 26% with first HF diagnosis at first hospitalization.
Patientswith renal dysfunctionweremore likely (HR1.12, p0.001)while patients
with COPD (HR0.85, p0.001) or stroke (HR0.64, p0.001) less likely to be hospi-
talized for HF. There was a lower hospitalization risk among patients who received
ACE inhibitors (HR0.72, p0.001), ARB (HR0.75, p0.001), -Blockers (HR0.81,
p0.001), or other CVmedications (HR0.75, p0.001). Patients diagnosed with HF
at first hospitalization were 2.33 times more likely to be re-hospitalized (p.001)
and risk also increased with age. African-Americans were more likely, than Cau-
casians (HR1.28, p0.001), other races less likely (HR0.60, p0.004), and men
(HR1.13) more likely to be hospitalized. CONCLUSIONS: Renal dysfunction con-
current with HF increased the likelihood of hospitalization, as did age,male gender
and African-American race. Understandably, HF patients on disease-modifying
therapies, but surprisingly those also diagnosed with COPD or stroke, were less
likely to be hospitalized. These findings deserve consideration as disease manage-
ment systems are developed in an era of health care transformation.
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OBJECTIVES:Volumemeasurements of the left ventricle are essential part of echo-
cardiographic diagnosis of canine heart diseases. Three-dimensional echocardiog-
raphy (3DE) has been rarely used in veterinary medicine mainly due to economic
limitations. A new technique now allows a fast semi-automatic direct measure-
ment with 3DE, additionally to the calculation of volumes according to reported
formulas, as used previously. This new method has proven in human medicine to
reveal comparable results to those obtained from the gold standardMRI. MRI is not
indicated in dogs suffering from heart failure, because of the necessity of general
anesthesia. The aim of this study was to compare results from conventional meth-
ods of echocardiographywith 3DE.METHODS: End-diastolic and end-systolic stan-
dard measurements of the left ventricle were performed in 42 healthy dogs (bea-
gles and dachshunds), including calculation of volume according to Teichholz
measurements using M-Mode, calculations of volume using single plane and bi-
plane method of discs (Simpson’s rule) with two-dimensional echocardiography
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